Your browser is no longer supported. Please, upgrade your browser.
Settings
JNJ Johnson & Johnson daily Stock Chart
JNJ [NYSE]
Johnson & Johnson
IndexDJIA S&P500 P/E22.21 EPS (ttm)5.37 Insider Own0.02% Shs Outstand2.74B Perf Week1.08%
Market Cap326.17B Forward P/E16.77 EPS next Y7.11 Insider Trans-10.99% Shs Float2.74B Perf Month0.15%
Income15.03B PEG3.41 EPS next Q1.65 Inst Own67.30% Short Float0.73% Perf Quarter1.51%
Sales70.88B P/S4.60 EPS this Y-3.90% Inst Trans-0.13% Short Ratio3.12 Perf Half Y10.91%
Book/sh26.40 P/B4.52 EPS next Y6.28% ROA11.10% Target Price126.76 Perf Year34.23%
Cash/sh15.57 P/C7.66 EPS next 5Y6.52% ROE20.90% 52W Range87.39 - 125.23 Perf YTD18.52%
Dividend3.20 P/FCF109.31 EPS past 5Y2.80% ROI16.90% 52W High-4.80% Beta0.64
Dividend %2.68% Quick Ratio2.70 Sales past 5Y2.60% Gross Margin69.60% 52W Low36.42% ATR1.09
Employees127100 Current Ratio3.10 Sales Q/Q3.90% Oper. Margin25.50% RSI (14)48.65 Volatility0.94% 0.87%
OptionableYes Debt/Eq0.36 EPS Q/Q-10.90% Profit Margin21.20% Rel Volume0.82 Prev Close117.78
ShortableYes LT Debt/Eq0.34 EarningsOct 18 BMO Payout55.90% Avg Volume6.43M Price119.22
Recom2.50 SMA200.34% SMA50-1.37% SMA2007.50% Volume5,275,100 Change1.22%
Jul-21-16Reiterated Deutsche Bank Hold $125 → $142
Jul-20-16Reiterated UBS Buy $126 → $137
Jul-20-16Reiterated RBC Capital Mkts Outperform $125 → $133
May-20-16Initiated Standpoint Research Sell $94
Apr-20-16Reiterated RBC Capital Mkts Outperform $122 → $125
Apr-20-16Reiterated Piper Jaffray Neutral $105 → $106
Apr-15-16Reiterated RBC Capital Mkts Outperform $114 → $122
Mar-14-16Upgrade Goldman Sell → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $101 → $115
Oct-05-15Resumed Piper Jaffray Neutral $105
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Dec-16-13Reiterated Deutsche Bank Hold $93 → $95
Jul-18-13Reiterated Argus Buy $96 → $104
Jul-17-13Reiterated Barclays Overweight $95 → $99
Sep-27-16 05:41PM  Blockbuster biotech deal coming?
05:13PM  Smithfield Foods Prepares for Major Cloud Migration at The Wall Street Journal
01:59PM  Perry Capitals Long-Term Holdings as It Plans to Wind Down at Insider Monkey
12:22PM  What Gives With Biosimilars? at Motley Fool
11:12AM  3 Top Stocks for Low-Risk Investors to Buy Now at Motley Fool
10:44AM  Amgen: The Blame Game at Barrons.com
10:14AM  AbbVie (ABBV) Files sNDA for Blood Cancer Drug Imbruvica
09:03AM  The 3 Best-Run Companies in the Healthcare Sector at Motley Fool
08:04AM  What Analysts Are Recommending for Johnson & Johnson Now
Sep-26-16 04:03PM  Wall Street Sells Off on Worries Over Clinton-Trump Showdown
02:38PM  Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies
12:36PM  Research finds talc doesn't cause cancer; juries disagree
12:04PM  J&J Finally Returning to Its Roots in Diversity?
11:46AM  vTv Therapeutics Shares Initiated With Buy Rating, $13 Target
11:05AM  A Look at Johnson & Johnsons Recent Stock Performance
10:50AM  New Crohns Disease Drug Approved by FDA
10:06AM  FDA approves J&J's autoimmune drug Stelara for Crohn's disease Reuters
10:05AM  Inside Johnson & Johnsons Latest US Medical Device Launch
09:00AM  Achillion, J&J HCV Triple Combination Drug Data Presented
08:56AM  Glaxo/J&J File BLA for Rheumatoid Arthritis Drug in the U.S.
08:06AM  Johnson & Johnson Gets FDA Approval for Type 2 Diabetes Drug
Sep-25-16 06:00PM  Naming and Shaming Palm-Oil Buyers to Stop Rainforest Burning at Bloomberg
07:11AM  Ignore Procter & Gamble: Here Are 3 Better Stocks at Motley Fool
Sep-24-16 11:53AM  McDonalds (MCD), Johnson & Johnson (JNJ) Among Hedge Funds Favorite Dividend Aristocrats at Insider Monkey
Sep-23-16 07:04PM  Generics or Specialty: Which Mylan Segment Is Growing Fastest?
05:35PM  Global Licensing Deal Spikes Geron Stock (GERN, JNJ) at Investopedia
05:07PM  The Rationale behind Johnson & Johnsons Acquisition of Abbott Medical Optics
01:06PM  Procter & Gamble Is Losing Shelf Space Clout at Investopedia
09:07AM  Hate Risk? You'll Love These 3 Stocks at Motley Fool
08:03AM  Better Buy: Pfizer Inc. vs. Johnson & Johnson at Motley Fool
08:00AM  Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO
07:38AM  Johnson & Johnson Is Setting Up for a Rally
Sep-22-16 04:20PM  Gilead Sciences Inc.'s Biggest Win in 2016 So Far at Motley Fool
03:53PM  Pepper: Stick with right sectors, right stocks for long t...
03:40PM  How Much Could DepoMed Fetch in a Deal? at Motley Fool
07:17AM  Better Buy: Procter & Gamble vs. Johnson & Johnson at Motley Fool
Sep-21-16 11:58AM  Johnson & Johnson (JNJ)s Janssen Builds On Partnership With Geron Corporation (GERN) at Insider Monkey
11:18AM  EpiPen Controversy: Mylan's Tough Week Just Keeps Getting Grimmer
10:04AM  How Procysbi Fits into Horizons Existing Orphan Drug Portfolio
08:16AM  Move Over, Intuitive Surgical, Here's How Johnson & Johnson and Google Plan to Build a Better Robot at Motley Fool
Sep-20-16 03:00PM  Johnson & Johnson Advances Commitment to Improve Global Health and Well-Being PR Newswire
11:18AM  Johnson & Johnson's Smart (Yet Surprising) Acquisition at Motley Fool
11:02AM  [$$] Abbott's Deal With JNJ Is Good Strategy at Barrons.com
09:30AM  Zacks.com featured highlights: Baxter International, AO Smith, Johnson & Johnson, BWX Technologies and Lancaster Colony
09:19AM  Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results PR Newswire
08:08AM  [$$] Big pharma targets drug-resistant superbugs at Financial Times
06:50AM  Pfizer (PFE) Breast Cancer Drug Ibrance Wins CHMP Backing
Sep-19-16 06:50PM  A Breakdown Here In This Sector Would Not Be Healthy
05:35PM  Abbott Laboratories -- Moody's expectations for Abbott's ratings unchanged following news of medical optics sale at Moody's
05:15PM  Isle of Capri, GM and Halliburton climb; WebMD drops
03:21PM  US stocks mostly higher as banks rise before Fed meeting
12:39PM  JOHNSON & JOHNSON Files SEC form 8-K, Other Events, Financial Statements and Exhibits
12:17PM  Apple Didn't Waste Billions on Its Buyback Program, but These Companies Did at Motley Fool
10:30AM  Stock Market News for September 19, 2016
10:16AM  Credit Suisse Can Clearly See Why Johnson & Johnson Acquired Abbott's Optics Division
10:00AM  J&J Buys Abbott's Eye Health Unit for $4.3 Billion at Investopedia
09:45AM  This Diabetes Breakthrough Is Great News or Terrible News, Depending on Your Perspective at Motley Fool
09:20AM  Blog Coverage Johnson and Johnson Acquires Abbott Laboratories Optic Unit
09:15AM  Blog Coverage Johnson & Johnson Acquires Abbott Laboratories Optic Unit Accesswire
08:52AM  5 Efficient Stocks to Ensure High Yields
08:16AM  J&J (JNJ) to Buy Abbott's Vision Care Unit for $4.3 Billion
Sep-18-16 12:08PM  Tesla, TerraForm, and Johnson & Johnson Among the Biggest Weekend Newsmakers at Insider Monkey
11:13AM  Hate Checking Your Portfolio? Try These 2 Stocks at Motley Fool
Sep-17-16 11:47AM  AP Top Extended Financial Headlines at 11:47 a.m. EDT
11:41AM  Is This New Market the Biggest Investment Idea of the Decade? at Motley Fool
Sep-16-16 11:43PM  [$$] J&J to Buy Abbotts Eye-Surgery Equipment Unit for $4.325 billion at The Wall Street Journal
07:13PM  The 3 Best Long-Term Dividend Stocks to Buy Now at Motley Fool
05:57PM  [$$] J&J to Buy Abbott's Eye-Surgery Unit for $4.325 billion at The Wall Street Journal
05:48PM  Abbott to sell its eye care business to J&J for about $4.33 billion
05:43PM  Abbott to sell its eye care business to J&J for about $4.33 bln
05:05PM  Johnson & Johnson Sees Growth in Ophthalmology, Acquires Abbott Medical Optics
04:13PM  Johnson & Johnson to buy Abbott's vision unit for $4.33B
04:10PM  Abbott is selling its vision unit to Johnson & Johnson at bizjournals.com
03:27PM  Abbott (ABT) Stock Higher as Johnson & Johnson to Buy Medical Optics Unit
03:18PM  Johnson & Johnson (JNJ) Stock Lower, Buys Abbott Laboratories' Medical Optics Unit for $4.3 Billion
03:16PM  Johnson & Johnson to buy Abbott Medical Optics for $4.33 billion in cash at CNBC
03:13PM  Johnson & Johnson to buy Abbott Labs medical optics subsidiary for $4.3bln at MarketWatch
03:06PM  J&J to Buy Abbott Eye Surgery Unit for $4.33 Billion at Bloomberg
03:00PM  Johnson & Johnson Announces Agreement to Acquire Abbott Medical Optics PR Newswire
01:23PM  Abbott in talks to sell its eye-surgery business to J&J - WSJ
01:13PM  Why DepoMed's Shares Are Jumping 12% Today at Motley Fool
12:15PM  Johnson & Johnson (JNJ) Stock Lower, Purchases 100 Megawatts of Texas Wind Power
11:21AM  CEOs say consumers are less confident
09:30AM  Johnson & Johnson Buying 100 Megawatts of Texas Wind Power at Bloomberg
09:03AM  Merck/Pfizer Diabetes Drug Ertugliflozin Positive in Phase III
08:12AM  Are We Unprepared For Another Ebola Outbreak? at Forbes
Sep-15-16 06:46PM  Is Johnson & Johnson Backing Away From a Growing Medical Devices Market?
05:18PM  Sarepta Shares Soar on News of Key Drug Critic FDA Exit
03:02PM  Sanofi (SNY) Presents Positive Diabetes Data on iGlarLixi (revised)
12:46PM  FDA Expands Indication for Strykers Trevo Technology
11:32AM  FDA Panel Suggests Removing Warning from Pfizer's Chantix
09:54AM  Novo Nordisk (NVO) Presents Data on Obesity Drug Saxenda
Sep-14-16 02:07PM  [$$] UK and US: Workplace tale of two healthcare systems at Financial Times
10:42AM  You'll Never Guess Which Pharma Could Knock Gilead Sciences Off Its HIV Throne at Motley Fool
09:14AM  Sanofi (SNY) Presents Positive Diabetes Data on iGlarLixi
08:04AM  3 Attractive Income Stocks Whose Dividends Could Double at Motley Fool
Sep-13-16 06:15PM  Barrow, Hanley, Mewhinney & Strauss Reduces Stakes in 2nd Quarter
05:05PM  Perrenial Target and Acquirer NuVasive Names New President and COO
10:40AM  5 Blue Chip Stocks You Can Buy Today at Motley Fool
10:08AM  Geron (GERN) at 52-Week Low on Imetelstat Study Update
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women's health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages under the BAND-AID brand name and first aid products under the NEOSPORIN brand name. This segment also provides over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company offers its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JOHNSON & JOHNSON10% OwnerAug 16Buy12.00583,3336,999,9962,449,183Aug 18 05:11 PM
Caruso Dominic JExec VP, Finance; CFOJul 26Option Exercise65.6241,1462,700,001157,819Jul 28 04:34 PM
Caruso Dominic JExec VP, Finance; CFOJul 26Sale125.0141,1465,143,810116,673Jul 28 04:34 PM
Kapusta Ronald AController, CAOJul 22Sale125.012,935366,89625,725Jul 25 03:18 PM
Kapusta Ronald AController, CAOJul 21Option Exercise58.332,935171,19928,660Jul 25 03:18 PM
Kapusta Ronald AController, CAOJun 07Option Exercise58.333,000174,99028,725Jun 09 04:11 PM
Pruden Gary JExec VP, WW Chair, Med DevicesJun 07Sale116.039,7351,129,55243,630Jun 09 04:12 PM
Kapusta Ronald AController, CAOJun 07Sale115.793,000347,38125,725Jun 09 04:11 PM
Kapusta Ronald AController, CAOMay 10Option Exercise58.333,957230,81229,682May 12 05:09 PM
Kapusta Ronald AController, CAOMay 10Sale114.773,957454,15725,725May 12 05:09 PM
Caruso Dominic JVP, Finance; CFOFeb 08Option Exercise0.0029,0050125,466Feb 10 06:02 PM
Gorsky AlexChairman, CEOFeb 08Option Exercise0.0067,9330197,441Feb 10 06:02 PM
PETERSON SANDRA EGroup Worldwide ChairmanFeb 08Option Exercise0.007,633037,943Feb 10 06:03 PM
Fasolo PeterVP, Global Human ResourcesFeb 08Option Exercise0.0018,777056,512Feb 10 06:03 PM
Ullmann Michael HVP, General CounselFeb 08Option Exercise0.0016,697098,071Feb 10 06:03 PM
Stoffels PaulusChief Scientific OfficerFeb 08Option Exercise0.0028,2420131,104Feb 10 06:03 PM
Kapusta Ronald AController, CAOFeb 08Option Exercise0.002,598026,023Feb 10 06:03 PM
Fasolo PeterVP, Global Human ResourcesFeb 03Option Exercise72.54144,56810,486,963182,303Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 03Sale104.12144,56815,052,42037,735Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 02Option Exercise72.546,817494,50544,552Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 02Sale104.096,817709,58837,735Feb 04 06:04 PM
Caruso Dominic JVP, Finance; CFOJan 15Option Exercise0.0011,6020100,336Jan 20 07:25 PM
Fasolo PeterVP, Global Human ResourcesJan 15Option Exercise0.007,511040,578Jan 20 07:25 PM
Gorsky AlexChairman, CEOJan 15Option Exercise0.0027,1730140,534Jan 20 07:25 PM
PETERSON SANDRA EGroup Worldwide ChairmanJan 15Option Exercise0.003,053031,616Jan 20 07:25 PM
Ullmann Michael HVP, General CounselJan 15Option Exercise0.006,679083,907Jan 20 07:25 PM
Kapusta Ronald AController, CAOJan 15Option Exercise0.003,896024,699Jan 20 07:25 PM
Stoffels PaulusChief Scientific OfficerJan 15Option Exercise0.0011,2970106,585Jan 20 07:25 PM
PETERSON SANDRA EGroup Worldwide ChairmanDec 17Option Exercise0.0021,688040,730Dec 21 05:09 PM
Ullmann Michael HVP, General CounselNov 20Option Exercise58.3422,6261,320,00194,878Nov 24 01:00 PM
Ullmann Michael HVP, General CounselNov 20Sale102.4717,6501,808,54377,228Nov 24 01:00 PM
Caruso Dominic JVP, Finance; CFONov 02Option Exercise58.3420,5691,199,995109,303Nov 04 05:05 PM
Caruso Dominic JVP, Finance; CFONov 02Sale102.2120,5692,102,42388,734Nov 04 05:05 PM
Kapusta Ronald AController, CAOOct 23Option Exercise58.346,239363,98327,042Oct 27 03:38 PM
Kapusta Ronald AController, CAOOct 23Sale99.686,239621,90420,803Oct 27 03:38 PM